Stockchase Opinions

Brad Willock IMS Health Inc RX-N BUY Feb 22, 2002

Has dropped because of earnings warnings. Should be okay at this level.
$19.430

Stock price when the opinion was issued

other services
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK
Controls 80% of their field.
TOP PICK
(Was a top pick on May 25 down 28%) Still likes. Expects 15% growth.
PAST TOP PICK
(Was a top pick on Nov 13 no change) Still likes. Growing their business at 12% a year. No debt.
TOP PICK
It is a proprietary global database for things like where drugs are being sold, who's prescribing, for what conditions, etc. About 8 times as large as their nearest competitor. Have has problems with their Japanese information which is now being corrected and they are coming back into profitability.
TOP PICK
They provide all the data to companies like Johnson & Johnson (JNJ-N) and Pfizer (PFE-N) on pharmaceuticals sales. If you are J&J and want to know what drug is selling where and how well they tell them. Now trading at 8X earnings. Very cheap.
TOP PICK
Relatively small company but the leading dominant provider of data to the pharmaceutical industry. When a drug company wants information about how its drugs are selling, what doctors are prescribing those drugs they go to this company. Great value at about 9X earnings.